BioLineRx announces collaboration with Washington University School of Medicine

BioLineRx announced a collaboration with Washington University School of Medicine in St. Louis to advance a Phase 1 clinical trial that will evaluate the safety and feasibility of the company’s lead clinical candidate motixafortide to mobilize CD34+ hematopoietic stem cells for gene therapies in sickle cell disease, one of the most common genetic diseases globally. Currently available mobilization regimens can carry serious risks and side effects for patients with SCD or may not reliably yield optimal numbers of HSCs for gene therapy. The clinical trial is part of the company’s long-term growth strategy for motixafortide across multiple therapeutic areas, including a potential future indication as a stem cell mobilization agent to support gene therapy development.